Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

INDV

+ Watchlist+ Portfolio

Indivior Pharmaceuticals, Inc.

Regulated industryPhysical productsTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$35.37
52-Week Range
$27.68 – $42.81
Market Cap
$4.28B
P/E (TTM)
10.16
EPS (TTM)
3.57
Dividend Yield
0.00%
Advanced Metrics
Price/Book
—
PEG Ratio
—
Return on Equity
—
Return on Assets
29.34%
Gross Margin
85.73%
Operating Margin
54.77%
Profit Margin
32.75%
Current Ratio
0.61
Debt/Equity
—
Total Debt
$501.00M
Free Cash Flow
$227.12M
Revenue Growth
13.40%
Earnings Growth
239.40%
Enterprise Value
$4.48B

Market Snapshot

About

Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to treating substance use disorders and serious mental illnesses. The company's portfolio includes medications for opioid dependence, including buprenorphine-based products marketed under various brand names. Indivior focuses on developing long-acting injectable formulations and abuse-deterrent technologies to improve treatment adherence and patient outcomes. The company combines pharmaceutical development with patient support programs to address the complex challenges of addiction treatment and recovery.